Risk factors and treatment outcomes of 1,375 patients with testicular leydig cell tumors: analysis of published case series data
Clarke, Noel W
AffiliationDepartment of Urology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
MetadataShow full item record
AbstractAbstract AIMS: Leydig cell tumors (LCTs) are rare but the most common non-germ cell testicular tumors. Only limited evidence exists for reliably differentiating between benign and malignant LCTs and for optimally managing the different types and stages of this rare disease. This review aims to synthesize the available evidence regarding the clinical presentation and clinicopathological characteristics associated with LCT malignancy and management. METHODS: We analyzed published case series with LCTs patients. The association between clinicopathological variables and the presence of metastatic disease was assessed using regression analyses. RESULTS: We included 357 reports, reviewing available data from 1,375 patients (median age: 34y). Testis-sparing surgery (TSS) was performed in 463 patients. Local recurrence after TSS occurred in 8 of 121 (7%) patients with available follow-up information. Metastases were found in 101 patients and were most often located in the retroperitoneal lymph nodes (60%), lungs (38%), and/or liver (29%). The multivariable models with or without multiple imputation predicting metastatic disease included older age, larger tumor size, the presence of any adverse factor (larger tumor diameter, necrosis, angiolymphatic invasion, pleomorphism, high mitotic index, atypia), and any protective factor (Reinke crystals, lipofuscin pigments, gynecomastia) with model AUCs of 0.93. Durable remission after resection of metastases or platinum-based chemotherapy was rarely seen. CONCLUSION: Our risk tables using clinicopathological parameters can help identify patients harboring malignant tumors. These patients should undergo staging and either be followed or receive further treatment. In metastatic disease surgical and systemic treatment might result in disease control in in some patients.
CitationFankhauser CD, Grogg JB, Hayoz S, Wettstein MS, Dieckmann KP, Sulser T, et al. Risk Factors and Treatment Outcomes of 1,375 Patients with Testicular Leydig Cell Tumors: Analysis of Published Case Series Data. J Urol. 2019:101097JU0000000000000705.
JournalJournal of urology
- Risk factors and treatment outcomes of 239 patients with testicular granulosa cell tumors: a systematic review of published case series data.
- Authors: Grogg JB, Schneider K, Bode PK, Kranzbühler B, Eberli D, Sulser T, Beyer J, Lorch A, Hermanns T, Fankhauser CD
- Issue date: 2020 Nov
- Leydig cell tumor of the testis: a clinicopathologic, DNA content, and MIB-1 comparison of nonmetastasizing and metastasizing tumors.
- Authors: Cheville JC, Sebo TJ, Lager DJ, Bostwick DG, Farrow GM
- Issue date: 1998 Nov
- Testicular tumors in children.
- Authors: Ciftci AO, Bingöl-Koloğlu M, Senocak ME, Tanyel FC, Büyükpamukçu M, Büyükpamukçu N
- Issue date: 2001 Dec
- Sertoli Cell Tumors of the Testes: Systematic Literature Review and Meta-Analysis of Outcomes in 435 Patients.
- Authors: Grogg J, Schneider K, Bode PK, Kranzbühler B, Eberli D, Sulser T, Lorch A, Beyer J, Hermanns T, Fankhauser CD
- Issue date: 2020 Jul
- Long-term followup after elective testis sparing surgery for Leydig cell tumors: a single center experience.
- Authors: Giannarini G, Mogorovich A, Menchini Fabris F, Morelli G, De Maria M, Manassero F, Loggini B, Pingitore R, Cavazzana A, Selli C
- Issue date: 2007 Sep